Study guide

11.4 Healthcare Regulations, Standards, and Drug Interactions

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

11.4 Healthcare Regulations, Standards, and Drug Interactions

Key Takeaways Explain This Topic AI

FDA, The Joint Commission (TJC), CMS, NIOSH, and USP <797>/<800> standards directly govern ICU medication safety, sterile compounding, hazardous drug handling, and the National Patient Safety Goals.

High-risk ICU drug interactions include QT prolongation (QTc >500 ms), serotonin syndrome (MAOIs + meperidine/tramadol/linezolid), cytochrome P450 induction/inhibition (CYP3A4 with azoles and macrolides), and pharmacodynamic potentiation of anticoagulants.

REMS (Risk Evaluation and Mitigation Strategy) programs for drugs like clozapine, esketamine, and isotretinoin require specific monitoring; VAERS handles vaccine adverse event reporting, and MedWatch covers general drug adverse events.

Drug-drug interaction screening integrated into CPOE and CDS systems must be tuned to reduce alert fatigue; pharmacists lead stewardship of override thresholds and high-priority alert criteria.

Last updated: July 2026

  • Healthcare Regulations, Standards, and Drug Interactions
  • Regulatory Bodies Governing ICU Pharmacy Practice

Body Scope Key ICU-Relevant Standards

FDA (Food and Drug Administration) Drug approval, labeling, REMS, post-marketing surveillance REMS for high-risk drugs (clozapine ANC monitoring, esketamine administration), MedWatch reporting

The Joint Commission (TJC) Hospital accreditation National Patient Safety Goals (NPSG): patient ID, hand hygiene, critical results reporting, medication reconciliation

CMS (Centers for Medicare & Medicaid Services) Reimbursement, Conditions of Participation Severe patient harm events (never events), CAUTI/CLABSI non-reimbursement, eCQM reporting

NIOSH (National Institute for Occupational Safety and Health) Worker safety Hazardous drug list (Group 1 antineoplastics, Group 2 non-antineoplastic hazardous, Group 3 reproductive hazards)

USP (United States Pharmacopeia) Compounding standards USP <797> sterile compounding; USP <800> hazardous drug handling

  • ASHP Professional practice Pharmacy practice standards, compounding, sterile prep guidelines
  • DEA Controlled substances Scheduling, ordering, dispensing, waste disposal
  • State Boards of Pharmacy State-specific oversight Varies; collaborative practice, remote order verification
  • REMS (Risk Evaluation and Mitigation Strategy)

REMS is an FDA-required risk management program for drugs with serious safety concerns. ICU-relevant REMS:

Clozapine: ANC monitoring (weekly x6 months, then biweekly x6 months, then monthly); stop if ANC <1000 (500 if benign ethnic neutropenia).

Esketamine: administered only in healthcare settings with monitoring for dissociation, sedation, blood pressure.

Isotretinoin: pregnancy prevention (iPLEDGE).

Mifepristone: prescriber agreement and patient agreement.

Thalidomide/lenalidomide/pomalidomide: pregnancy prevention, CBC monitoring.

Adverse Event Reporting Systems

MedWatch: FDA voluntary and mandatory reporting of adverse drug events, device events, nutritional events.

VAERS (Vaccine Adverse Event Reporting System): co-managed by FDA and CDC for vaccine adverse events.

FAERS (FDA Adverse Event Reporting System): supports post-marketing safety surveillance.

MedMARx: medication error reporting database.

ISMP (Institute for Safe Medication Practices): voluntary confidential reporting; publishes safety alerts.

USP <797> and USP <800> in ICU Pharmacy

USP <797>: sterile compounding standards — ISO Class 5 environment, beyond-use dating, CSP categories (immediate-use, low-risk, medium-risk, high-risk), environmental monitoring.

USP <800>: hazardous drug handling — required for any entity storing, preparing, or dispensing hazardous drugs; negative pressure compounding room (ISO Class 7), external venting, closed-system transfer devices (CSTDs) for administration, PPE for handling, separate storage.

  • Drug-Drug Interactions in the ICU
  • QT Prolongation

QTc >500 ms increases torsade de pointes risk. ICU high-risk combinations:

Antiarrhythmics: amiodarone, sotalol, dofetilide, ibutilide, dronedarone.

Antimicrobials: macrolides (azithromycin lower risk), fluoroquinolones (moxifloxacin highest), fluconazole/voriconazole.

Psychiatric: haloperidol, droperidol, methadone, SSRIs (mostly citalopram).

Antiemetics: ondansetron (low but additive).

Plus electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) and bradycardia.

Mitigation: correct electrolytes, avoid QT stacking, daily QTc monitoring, alternative agents (e.g., azithromycin → doxycycline, ondansetron → palonosetron).

Serotonin Syndrome

Triad: mental status change, autonomic instability (hyperthermia, tachycardia, hypertension), neuromuscular hyperactivity (clonus, hyperreflexia, rigidity).

Culprit combinations:

MAOI + meperidine/tramadol/linezolid/SSRI/SNRI/TCAs.

Linezolid + serotonergic psychiatric meds.

Tramadol + SSRI/SNRI.

Fentanyl + SSRI (rare, controversial).

Treatment: stop serotonergic agents, supportive care (cooling, benzodiazepines for rigidity, cyproheptadine 12 mg PO/NG initially then 2-8 mg q2-6h up to 32 mg/day in severe cases).

Cytochrome P450 Interactions

Substrate Class Strong Inhibitors (CYP3A4) Strong Inducers (CYP3A4)

Tacrolimus, cyclosporine, sirolimus, midazolam, fentanyl, voriconazole Ketoconazole, voriconazole, clarithromycin, ritonavir, diltiazem, grapefruit Rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort

CYP2C9 (warfarin, phenytoin): amiodarone, fluconazole, sulfamethoxazole inhibit; carbamazepine, rifampin induce.

CYP2D6 (codeine, tramadol, metoprolol): fluoxetine, paroxetine, bupropion inhibit.

Pharmacodynamic Interactions

Anticoagulant stacking: DOAC + antiplatelet + NSAID sharply increases bleeding; deprescribe when indications allow.

Nephrotoxin stacking: vancomycin + piperacillin-tazobactam increases AKI risk vs. vancomycin + cefepime.

CNS depression: opioids + benzodiazepines + gabapentinoids increase respiratory depression; lowest effective doses, monitor sedation.

QT + Bradycardia: beta-blocker + non-dihydropyridine CCB may precipitate heart block.

CDS and Alert Fatigue

Computerized provider order entry (CPOE) with embedded drug interaction alerts reduces interactions but suffers alert fatigue: 90%+ override rate. Strategies:

Tier alerts by severity (mild/ moderate/ severe/ contraindicated).

Suppress duplicate-therapy alerts for therapeutically equivalent same-class switches.

Build patient-specific factors (renal function, age, weight, electrolytes) into trigger logic.

Pharmacist review of overridden alerts with feedback to prescribers.

Use interruptive alerts only for clinically significant interactions.

Clinical Scenario

A stem cell transplant patient on tacrolimus (trough 8 ng/mL) develops invasive aspergillosis and is started on voriconazole. Three days later, tacrolimus trough is 25 ng/mL with acute kidney injury. What is the mechanism and management?

Answer: Voriconazole is a potent CYP3A4 inhibitor; tacrolimus is a CYP3A4 substrate. Inhibition reduces tacrolimus clearance, causing accumulation and nephrotoxicity. Management: reduce tacrolimus dose to one-third of prior and monitor every 2-3 days; consider switching to isavuconazole (less CYP3A4 inhibition) or posaconazole (moderate). Continue voriconazole for invasive aspergillosis. Resume standard tacrolimus dose as voriconazole is tapered.